Skip to content

Mineralys Therapeutics, Inc. MLYS Professional service fees

Professional service fees at other companies

Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM

Other financials

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%
CapEx$15.0K
Free cash flow-$37.9M+43.3%

Valuation

See full
Market cap$2.27B+124%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mineralys Therapeutics, Inc.'s professional service fees.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mineralys Therapeutics, Inc.'s professional service fees?
Mineralys Therapeutics, Inc. (MLYS) reported professional service fees of $6.7M in Q1 2026.
How has Mineralys Therapeutics, Inc.'s professional service fees changed year-over-year?
Mineralys Therapeutics, Inc.'s professional service fees increased by 204.3% year-over-year, from $2.2M to $6.7M.
What is the long-term trend for Mineralys Therapeutics, Inc.'s professional service fees?
Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s professional service fees has grown at a 84.8% compound annual growth rate (CAGR), from $649K to $4.1M.